Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Takeda's two approvals come as ...

Add Yahoo as a preferred source to see more of our stories on Google. A Takeda logo is seen in its research hub in Cambridge, Massachusetts, U.S., November 26, 2018. Picture taken November 26, 2018.

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. The Food and Drug Administration on ...

Alex Zhavoronkov, Founder, CEO & CBO of Insilico Medicine, says the Takeda deal lets the company scale beyond its own pipeline and become a top global player in AI drug discovery. He breaks down the ...

Japanese pharmaceutical major Takeda is forging an AI drug-discovery partnership with biotech firm Insilico Medicine with a potential initial value of $600.0 million. Under the partnership announced ...

Most disputes between pharmaceutical companies and generic drugmakers end in settlements. Five years of class-action litigation over a Takeda Pharmaceutical gastrointestinal drug culminated this week ...

Patent settlement unlawfully delayed generic competition for Amitiza. When drug makers pay would‑be generic competitors to stay off the market, businesses and consumers absorb the cost in the form of ...

Massachusetts’ largest life sciences employer has been found liable for roughly $885 million in damages — and that figure could balloon past $2.4 billion. A federal jury in Boston determined that ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Plaintiffs said Takeda's generic settlement with Par caused them to overpay for Amitiza. (Takeda) Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case ...

May 13 (Reuters) - Japan's Takeda Pharmaceutical (4502.T), opens new tab, plans to cut about 4,500 jobs in fiscal year 2026, as part of ‌a restructuring to centralize corporate functions and reduce ...